These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 32890415)

  • 1. Enantioselective Total Synthesis of (-)-Finerenone Using Asymmetric Transfer Hydrogenation.
    Lerchen A; Gandhamsetty N; Farrar EHE; Winter N; Platzek J; Grayson MN; Aggarwal VK
    Angew Chem Int Ed Engl; 2020 Dec; 59(51):23107-23111. PubMed ID: 32890415
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of BAY 94-8862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases.
    Bärfacker L; Kuhl A; Hillisch A; Grosser R; Figueroa-Pérez S; Heckroth H; Nitsche A; Ergüden JK; Gielen-Haertwig H; Schlemmer KH; Mittendorf J; Paulsen H; Platzek J; Kolkhof P
    ChemMedChem; 2012 Aug; 7(8):1385-403. PubMed ID: 22791416
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Asymmetric ruthenium-catalyzed hydrogenation of 2,6-disubstituted 1,5-naphthyridines: access to chiral 1,5-diaza-cis-decalins.
    Zhang J; Chen F; He YM; Fan QH
    Angew Chem Int Ed Engl; 2015 Apr; 54(15):4622-5. PubMed ID: 25694113
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DFT study of the mechanism and origin of enantioselectivity in chiral BINOL-phosphoric acid catalyzed transfer hydrogenation of ketimine and α-imino ester using benzothiazoline.
    Shibata Y; Yamanaka M
    J Org Chem; 2013 Apr; 78(8):3731-6. PubMed ID: 23521654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biotransformation of Finerenone, a Novel Nonsteroidal Mineralocorticoid Receptor Antagonist, in Dogs, Rats, and Humans, In Vivo and In Vitro.
    Gerisch M; Heinig R; Engelen A; Lang D; Kolkhof P; Radtke M; Platzek J; Lovis K; Rohde G; Schwarz T
    Drug Metab Dispos; 2018 Nov; 46(11):1546-1555. PubMed ID: 30171161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of nonsteroidal mineralocorticoid receptor antagonists in patients with diabetic kidney disease.
    Lerma E; White WB; Bakris G
    Postgrad Med; 2023 Apr; 135(3):224-233. PubMed ID: 35392754
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone Improves Diastolic Dysfunction in Preclinical Nondiabetic Chronic Kidney Disease.
    Lima Posada I; Soulié M; Stephan Y; Palacios Ramirez R; Bonnard B; Nicol L; Pitt B; Kolkhof P; Mulder P; Jaisser F
    J Am Heart Assoc; 2024 Jun; 13(12):e032971. PubMed ID: 38842271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of Finerenone, a Novel Nonsteroidal Mineralocorticoid Receptor Antagonist, on Cardiovascular Disease, Chronic Kidney Disease, and Blood Pressure.
    Ravid JD; Laffin LJ
    Curr Cardiol Rep; 2022 Oct; 24(10):1251-1259. PubMed ID: 35925515
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Finerenone : third-generation mineralocorticoid receptor antagonist for the treatment of heart failure and diabetic kidney disease.
    Liu LC; Schutte E; Gansevoort RT; van der Meer P; Voors AA
    Expert Opin Investig Drugs; 2015; 24(8):1123-35. PubMed ID: 26095025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Borane-catalyzed metal-free hydrogenation of 2,7-disubstituted 1,8-naphthyridines.
    Wang W; Feng X; Du H
    Org Biomol Chem; 2016 Jul; 14(28):6683-6. PubMed ID: 27334098
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Finerenone: a mineralocorticoid receptor antagonist for the treatment of chronic kidney disease associated with type 2 diabetes.
    Lerma EV; Wilson DJ
    Expert Rev Clin Pharmacol; 2022 May; 15(5):501-513. PubMed ID: 35762406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Direct Blood Pressure-Independent Anti-Fibrotic Effects by the Selective Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone in Progressive Models of Kidney Fibrosis.
    Droebner K; Pavkovic M; Grundmann M; Hartmann E; Goea L; Nordlohne J; Klar J; Eitner F; Kolkhof P
    Am J Nephrol; 2021; 52(7):588-601. PubMed ID: 34515038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury.
    Kolkhof P; Delbeck M; Kretschmer A; Steinke W; Hartmann E; Bärfacker L; Eitner F; Albrecht-Küpper B; Schäfer S
    J Cardiovasc Pharmacol; 2014 Jul; 64(1):69-78. PubMed ID: 24621652
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phosphoric acid catalyzed enantioselective transfer hydrogenation of imines: a density functional theory study of reaction mechanism and the origins of enantioselectivity.
    Marcelli T; Hammar P; Himo F
    Chemistry; 2008; 14(28):8562-71. PubMed ID: 18683177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benzothiazoline: versatile hydrogen donor for organocatalytic transfer hydrogenation.
    Zhu C; Saito K; Yamanaka M; Akiyama T
    Acc Chem Res; 2015 Feb; 48(2):388-98. PubMed ID: 25611073
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone Protects Against Acute Kidney Injury-Mediated Chronic Kidney Disease: Role of Oxidative Stress.
    Lattenist L; Lechner SM; Messaoudi S; Le Mercier A; El Moghrabi S; Prince S; Bobadilla NA; Kolkhof P; Jaisser F; Barrera-Chimal J
    Hypertension; 2017 May; 69(5):870-878. PubMed ID: 28320854
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Finerenone: Efficacy of a New Nonsteroidal Mineralocorticoid Receptor Antagonist in Treatment of Patients With Chronic Kidney Disease and Type 2 Diabetes.
    Dey S; Garg J; Wang A; Holzner E; Frishman WH; Aronow WS
    Cardiol Rev; 2024 May-Jun 01; 32(3):285-288. PubMed ID: 36946916
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Behlen MJ; Uyeda C
    J Am Chem Soc; 2020 Oct; 142(41):17294-17300. PubMed ID: 32972140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Direct enantioselective access to 4-substituted tetrahydroquinolines by catalytic asymmetric transfer hydrogenation of quinolines.
    Rueping M; Theissmann T; Stoeckel M; Antonchick AP
    Org Biomol Chem; 2011 Oct; 9(19):6844-50. PubMed ID: 21837348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Finerenone Reduces New-Onset Atrial Fibrillation in Patients With Chronic Kidney Disease and Type 2 Diabetes.
    Filippatos G; Bakris GL; Pitt B; Agarwal R; Rossing P; Ruilope LM; Butler J; Lam CSP; Kolkhof P; Roberts L; Tasto C; Joseph A; Anker SD;
    J Am Coll Cardiol; 2021 Jul; 78(2):142-152. PubMed ID: 34015478
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.